I note that Jefferies isn’t one of the 12 analysts listed.
And while there are 20 covering analyst firms listed on Acadia’s website, Jefferies isn’t one of them.
But I believe it once did provide coverge.
On March 13 2023 (just after DayBue approval) a Jefferies analyst put a Sell on ACAD, with a $15 price target.
Previously, on 17 June 2022, Jefferies upgraded ACAD from Neutral to Buy, with a Price Target of $25, but then downgraded to Underperform with a Price Target of just $10 on 21 June, 2022, after a negative FDA drug advisory committee outcome for Nuplazid.
Jefferies commenced coverage of Neuren in June 2022.
I note that Jefferies isn’t one of the 12 analysts listed. And...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.63 |
Change
-1.080(6.46%) |
Mkt cap ! $1.997B | |||
| Open | High | Low | Value | Volume |
| $16.61 | $16.65 | $15.54 | $8.354M | 529.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 830 | $15.60 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.74 | 1484 | 2 |
View Market Depth
| Last trade - 16.10pm 18/11/2024 (20 minute delay) ? |
| NEU (ASX) Chart |